Chinese biotech developing targeted therapies for cancer and autoimmune disease, led by BTK-inhibitor orelabrutinib.
Chinese biotech developing targeted therapies for cancer and autoimmune disease, led by BTK-inhibitor orelabrutinib.
Sells orelabrutinib mainly in China, where hospital access depends on the national reimbursement list, which trades a negotiated lower price for broader coverage. Licensing is a second route: partners can pay upfront and milestone fees for rights outside China. It listed in Hong Kong in 2020 and added a Shanghai STAR Market listing in 2022.
In one line: A Chinese BeiGene-style oncology/immunology biotech.
Moat: narrow (IP / patents, first-mover approval). Own BTK inhibitor approved in China with patent protection.
Headquarters: Beijing, China · Founded: 2015 · Employees: 1,259
Size InnoCare Pharma (9969.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $2.01B, the 410th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$10.82 on 18 Nov 2026.
Performance Over six months the shares fell 10.3%, against -1.3% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue grew 146.3% over the last twelve months (peer median +10.7%); the operating margin is 35.2% (peer median 20.9%).
Valuation It trades at 32.2× forward earnings against a peer median of 18.1× (5th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +341%, so the hurdle is -343 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 16.6 points above its cost of capital (10.0% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$3.80B | HK$2.56B | HK$1.08B | HK$810M | HK$722M |
| Revenue growth | — | +136% | +34% | +12% | — |
| Gross profit | HK$3.53B | HK$2.24B | HK$827M | HK$571M | HK$473M |
| EBITDA | n/a | HK$619M | -HK$475M | -HK$673M | -HK$824M |
| Net income | HK$1.53B | HK$697M | -HK$478M | -HK$698M | -HK$1.03B |
| Free cash flow | HK$412M | HK$146M | -HK$336M | -HK$886M | -HK$887M |
| Capital expenditure | HK$152M | HK$76.1M | HK$84.8M | HK$281M | HK$431M |
| Total debt | HK$2.49B | HK$1.79B | HK$1.68B | HK$1.82B | HK$385M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| InnoCare Pharma 9969.HK | $2.01B | -10% | +146% | 35% | 32.2× | -2.0% |
| Innovent Biologics 1801.HK | $18.9B | +4% | +43% | 17% | 52.3× | 11.6% |
| Akeso 9926.HK | $7.01B | -48% | +42% | -25% | n/a | n/a |
| AstraZeneca AZN.L | $278B | -2% | +5% | 23% | 17.6× | 14.4% |
| Lilly (Eli) LLY | $1.30T | +36% | +46% | 51% | 29.5× | 6.5% |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 24.2× | 3.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 9969.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.4% | +2.7% | 3rd lowest of 21 |
| 6-month return | -10.3% | -1.3% | 9th lowest of 21 |
| Distance from 52-week high | -33.2% | -28.2% | 6th lowest of 21 |
| Revenue growth (TTM) | +146.3% | +10.7% | highest of 20 |
| Operating margin | 35.2% | 20.9% | 2nd highest of 20 |
| Forward P/E | 32.2× | 18.1× | 5th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | -2.0% | 3.2% | 4th least demanding of 14 |
| Growth delivered (Del g) | +341.1% | +14.1% | highest of 14 |
| Hurdle (Req g minus delivered) | -343.1 pp | -12.4 pp | least demanding of 14 |
| ROIC minus cost of capital | +16.6 pp | +0.1 pp | 6th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| InnoCare Pharma 9969.HK | Hong Kong | $2.01B | -10% | +146% | 35% | 32.2× | -2.0% | +341.1% |
| Hanall Biopharma 009420.KS | South Korea | $2.01B | +12% | +5% | 3% | n/a | n/a | n/a |
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.02B | -45% | 0% | -47% | n/a | n/a | n/a |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.03B | +19% | -1% | 14% | 16.9× | 1.7% | +15.7% |
| Eris Lifesciences ERIS.NS | India | $1.98B | 0% | +11% | 26% | 27.9× | 26.3% | +20.9% |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.03B | -3% | +9% | 14% | 25.9× | 5.1% | +6.4% |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.04B | +9% | +5% | 22% | 15.9× | -4.7% | +10.6% |
| Biohaven BHVN | United States | $1.95B | +46% | n/a | n/a | n/a | n/a | n/a |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.95B | -14% | +11% | 6% | 44.6× | n/a | n/a |
| Harmony Biosciences HRMY | United States | $1.94B | +6% | +20% | 22% | 8.6× | -10.5% | +40.3% |
| Haw Par H02.SI | Singapore | $2.08B | -25% | -13% | 30% | 11.9× | 3.2% | +15.7% |
| Jinyu Bio-Technology 600201.SS | China | $1.93B | -21% | +22% | 10% | 59.0× | 23.4% | -2.5% |
| Tsumura & 4540.T | Japan | $1.93B | +6% | +13% | 18% | 10.4× | n/a | n/a |
| Grand Pharmaceutical 0512.HK | Hong Kong | $1.93B | -25% | +7% | 13% | 9.4× | 1.2% | +14.1% |
| Shilpa Medicare SHILPAMED.NS | India | $1.91B | +94% | +37% | 21% | 54.3× | n/a | n/a |
| PharmaResearch 214450.KS | South Korea | $2.10B | -24% | +29% | 37% | 15.4× | -11.0% | +37.6% |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 23.8× | 20.1% | +6.2% |
| Pfizer PFIZER.NS | India | $1.88B | -20% | +12% | 34% | 21.9× | 11.2% | +2.4% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $1.88B | -12% | -9% | 30% | 18.1× | 8.0% | +9.3% |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.87B | -8% | +13% | 27% | 12.5× | -1.2% | +16.7% |
| Cohance Lifesciences COHANCE.NS | India | $1.87B | +7% | +14% | 2% | 96.3× | n/a | n/a |